PharmaSGP Holding SE

  • WKN: A2P4LJ
  • ISIN: DE000A2P4LJ5
  • Land: Deutschland

Nachricht vom 15.09.2021 | 18:58

PharmaSGP Holding SE raises forecast for FY 2021 following completion of acquisition of OTC brand portfolio

PharmaSGP Holding SE / Key word(s): Change in Forecast
PharmaSGP Holding SE raises forecast for FY 2021 following completion of acquisition of OTC brand portfolio

15-Sep-2021 / 18:58 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Publication of inside information pursuant to Article 17 of Regulation (EU) No. 596/2014

PharmaSGP Holding SE raises forecast for FY 2021 following completion of acquisition of OTC brand portfolio

Gräfelfing, September 15, 2021 - Following the scheduled closing on August 31, 2021 of the agreement signed with the GlaxoSmithKline Group on the acquisition of an OTC portfolio with the brands Baldriparan(R), Formigran(R), Spalt(R) and Kamol(R) (the "GSK Portfolio"), PharmaSGP Holding SE is adjusting its revenues and earnings guidance for the 2021 financial year. This was decided by the company's Management Board today. Revenues as well as the adjusted earnings before interest, taxes, depreciation and amortization (adjusted EBITDA) of the PharmaSGP Group, which replaces the previous performance indicator "adjusted earnings before interest and taxes (adjusted EBIT)", serve as key performance indicators.

Previously, revenues of between € 56 million and € 60 million (2020: € 63.2 million) were expected for fiscal 2021, excluding any acquisitions, with a stable to slightly positive development of the "Health Brands" category and a declining "Beauty" business as expected. For the adjusted EBIT margin, the company had forecast an increase to between 27% and 30% (2020: 26.1 %); this corresponds to an adjusted EBITDA margin of between 28% and 31% (2020: 26.9 %). Including the revenues and earnings contributions of the GSK portfolio from September 1, 2021 onwards, the Management Board now expects full-year 2021 revenues of between € 60 million and € 65 million and an adjusted EBITDA margin of between 27 % and 31 %.

Note: The key performance indicators "Adjusted EBIT" and "Adjusted EBITDA" are not key performance indicators under IFRS. The adjustments used to derive adjusted EBITDA correspond to those used for adjusted EBIT. Information on this is available in the PharmaSGP Holding SE Annual Report 2020 on p. 37 (available at https://ir.pharmasgp.com).
 


15-Sep-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

IPO im Fokus

MIT SICHERHEIT AUFS PARKETT. UNSER BÖRSENGANG ZUR WACHSTUMSBESCHLEUNIGUNG

ISIN: DE000A3CM708
Grundkapital (vor IPO): 3.120.000 EUR
Angebotene Aktien: bis zu 690.000 Aktien
Zeichnungsfrist: 11.10.2021 bis voraus. 25.10.2021
Bookbuildingspanne: 3,30 bis 3,60 Euro
Börse: Börse Düsseldorf

Rechtlich maßgeblicher Wertpapierprospekt auf sdm-se.de

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“

GBC im Fokus

Börsengang sdm SE: Attraktives Investment

Der Sicherheitsdienstleister sdm SE führt derzeit einen Börsengang am Primärmarkt der Börse Düsseldorf durch. Die Mittel des Börsengangs sollen die Wachstumsstrategie finanzieren und die Ertragskraft deutlich steigern. Im Rahmen unseres DCF-Bewertungsmodells haben wir einen fairen Unternehmenswert (Post Money) zum Ende des Geschäftsjahres 2022 in Höhe von 15,23 Mio. € bzw. 4,09 € je sdm-Aktie ermittelt. Unter einem Preis von 3,50 € pro Aktie sehen wir sdm als ein attraktives Investment und stufen die Aktie mit dem Rating „Kaufen“ ein.

News im Fokus

Linde Starts Up Major New Hydrogen Facility in the U.S. Gulf Coast

21. Oktober 2021, 12:00

Aktueller Webcast

TRATON SE

Pressekonferenz – Zwischenmitteilung 9M 2021 - Webcast

28. Oktober 2021

Aktuelle Research-Studie

Aves One AG

Original-Research: Aves One AG (von GBC AG): Halten

21. Oktober 2021